While both anti-ER and anti-HER2 were developed to target key genes essential for ER+ and HER2+ BC, respectively, the development of alternative targeted therapies has been challenging due to the large degree of tumor heterogeneity and the presence of a large number of non-cancerous cells within the tumor, thereby masking key tumor driver genes. Here, ESR1 is linked to neoplasm.